Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with 'curative' intent

Autor: P. Romanelli, Marta Scorsetti, Andrei Fodor, Giovanni Ivaldi, Olga Oneta, Barbara Alicja Jereczek-Fossa, Isa Bossi Zanetti, G. Catalano, Stefano Maria Magrini, Michela Buglione, Giancarlo Beltramo, Paolo Antognoni, Nadia Di Muzio, Marianna Alessandra Gerardi, Davide Tomasini, Antonio Laudati, Paolo Borghetti, Davide Franceschini, Marco Lorenzo Bonù, Ciro Franzese, Italo Dell'Oca
Přispěvatelé: Buglione, M., Jereczek-Fossa, B. A., Bonu, M. L., Franceschini, D., Fodor, A., Zanetti, I. B., Gerardi, M. A., Borghetti, P., Tomasini, D., Di Muzio, N. G., Oneta, O., Scorsetti, M., Franzese, C., Romanelli, P., Catalano, G., Dell'Oca, I., Beltramo, G., Ivaldi, G. B., Laudati, A., Magrini, S. M., Antognoni, P.
Rok vydání: 2019
Předmět:
0301 basic medicine
Pulmonary and Respiratory Medicine
Male
Cancer Research
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
non-small cell lung cancer (NSCLC)
Adenocarcinoma of Lung
Ablative treatments
Radiosurgery
Metastasis
Stereotactic radiosurgery (SRS)
03 medical and health sciences
0302 clinical medicine
Non small cell lung cancer (NSCLC)
Carcinoma
Non-Small-Cell Lung
Medicine
Humans
Progression-free survival
Lung cancer
Aged
Retrospective Studies
Aged
80 and over
Univariate analysis
Oligometastasis
business.industry
Stereotactic radiotherapy (SRT)
Middle Aged
medicine.disease
Prognosis
Combined Modality Therapy
Radiation therapy
Survival Rate
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Carcinoma
Squamous Cell
Female
Radiology
Dose Fractionation
Radiation
business
Brain metastasis
Follow-Up Studies
Zdroj: Lung cancer (Amsterdam, Netherlands). 141
ISSN: 1872-8332
Popis: Objectives: stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) are a therapeutic option for Oligometastatic/Oligoprogressive (OM/OP) NSCLC. This retrospective multicentre analysis aims to analyse clinical outcomes and treatment related toxicity of patients treated to all sites of know disease with SRS and/or FSRT for OM/OP NSCLC in 8 Italian radiation oncology centres. Materials and methods: From January 2016 to January 2017 198 OM/OP NSCLC patients (pts) were treated in 8 Centres. Inclusion criteria were as follows: 1–5 lesions at onset or after previous systemic treatment; Pts must have all metastatic lesions treated. Endpoints analysed were local progression free survival (LPFS); out-of-field recurrence free survival (OFPS); progression free survival (PFS); overall survival (OS). Time to New systemic Therapy free survival (TNT) and toxicity were also analysed. Results: At the time of radiotherapy, 119 pts (60 %) were treated for a single lesion, 49 (25 %) for 2 lesions, 30 (15 %) for 3–5 metastases. Total number of lesions treated was 333: 204 brain, 68 lung, 24 bone, 16 nodal, 12 adrenal, 8 liver and 1 soft tissue. 83/198 pts (41.8 %) had the primary tumour controlled at the time of the SRT. After a median follow-up of 18 months, median OS and PFS were 29.6 months and 10.6 months, respectively. One year LPFS and OPFS were 90 % and 47 %, respectively. Median TNT was 10 months. At univariate analysis factors associated with better OS were PS 0–1; controlled primary tumour, 1–2 lesions; extracranial metastasis. Multivariate analysis confirmed number of lesions
Databáze: OpenAIRE
Externí odkaz: